Allogeneic bone marrow stem cell transplantation following CD34+ immunomagnetic enrichment in patients with inherited metabolic storage diseases

G. Gaipa; M. Dassi; P. Perseghin; N. Venturi; P. Corti; S. Bonanomi; A. Balduzzi; D. Longoni; C. Uderzo; A. Biondi; G. Masera; R. Parini; B. Bertagnolio; G. Uziel; C. Peters; A. Rovelli

doi:10.1038/sj.bmt.1704024

Allogeneic bone marrow stem cell transplantation following CD34+ immunomagnetic enrichment in patients with inherited metabolic storage diseases

G. Gaipa, M. Dassi, P. Perseghin, N. Venturi, P. Corti, S. Bonanomi, A. Balduzzi, D. Longoni, C. Uderzo, A. Biondi, G. Masera, R. Parini, B. Bertagnolio, G. Uziel, C. Peters, A. Rovelli

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

T-cell depletion is an essential step in reducing the risk of graft-versus-host disease (GVHD) in patients with inherited metabolic storage diseases (IMSD) undergoing hematopoietic stem cell transplantation. This goal can be achieved either by selective removal of T cells or by positive selection of CD34+ cells. Large-scale preparations of purified CD34+ cells from bone marrow products have not been extensively described. We report our results with bone marrow CD34+ cell enrichment using the CliniMACS system in eight children with IMSD. The median recovery of positively selected CD34+ cells was 46.2% with a purity of 97.5%, and a residual T cell content of 0.04 × 10⁶ . A median of 5.5 × 10⁶/kg of CD34+ cells was infused. All patients engrafted at a median time of 12 days and none of the patients developed GVHD. This method is technically feasible and can be successfully used to transplant children with IMSD.

Original language	English
Pages (from-to)	857-860
Number of pages	4
Journal	Bone Marrow Transplantation
Volume	31
Issue number	10
DOIs	https://doi.org/10.1038/sj.bmt.1704024
State	Published - May 2003
Externally published	Yes

Keywords

Hematopoietic stem cell
Immunomagnetic enrichment
Storage diseases
Transplantation

Access to Document

10.1038/sj.bmt.1704024

Cite this

Gaipa, G., Dassi, M., Perseghin, P., Venturi, N., Corti, P., Bonanomi, S., Balduzzi, A., Longoni, D., Uderzo, C., Biondi, A., Masera, G., Parini, R., Bertagnolio, B., Uziel, G., Peters, C., & Rovelli, A. (2003). Allogeneic bone marrow stem cell transplantation following CD34+ immunomagnetic enrichment in patients with inherited metabolic storage diseases. Bone Marrow Transplantation, 31(10), 857-860. https://doi.org/10.1038/sj.bmt.1704024

@article{a1118a389a164ed2bc71dfa7cca7fa2e,

title = "Allogeneic bone marrow stem cell transplantation following CD34+ immunomagnetic enrichment in patients with inherited metabolic storage diseases",

abstract = "T-cell depletion is an essential step in reducing the risk of graft-versus-host disease (GVHD) in patients with inherited metabolic storage diseases (IMSD) undergoing hematopoietic stem cell transplantation. This goal can be achieved either by selective removal of T cells or by positive selection of CD34+ cells. Large-scale preparations of purified CD34+ cells from bone marrow products have not been extensively described. We report our results with bone marrow CD34+ cell enrichment using the CliniMACS system in eight children with IMSD. The median recovery of positively selected CD34+ cells was 46.2% with a purity of 97.5%, and a residual T cell content of 0.04 × 106 . A median of 5.5 × 106/kg of CD34+ cells was infused. All patients engrafted at a median time of 12 days and none of the patients developed GVHD. This method is technically feasible and can be successfully used to transplant children with IMSD.",

keywords = "Hematopoietic stem cell, Immunomagnetic enrichment, Storage diseases, Transplantation",

author = "G. Gaipa and M. Dassi and P. Perseghin and N. Venturi and P. Corti and S. Bonanomi and A. Balduzzi and D. Longoni and C. Uderzo and A. Biondi and G. Masera and R. Parini and B. Bertagnolio and G. Uziel and C. Peters and A. Rovelli",

year = "2003",

month = may,

doi = "10.1038/sj.bmt.1704024",

language = "English",

volume = "31",

pages = "857--860",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Springer Nature",

number = "10",

}

Gaipa, G, Dassi, M, Perseghin, P, Venturi, N, Corti, P, Bonanomi, S, Balduzzi, A, Longoni, D, Uderzo, C, Biondi, A, Masera, G, Parini, R, Bertagnolio, B, Uziel, G, Peters, C & Rovelli, A 2003, 'Allogeneic bone marrow stem cell transplantation following CD34+ immunomagnetic enrichment in patients with inherited metabolic storage diseases', Bone Marrow Transplantation, vol. 31, no. 10, pp. 857-860. https://doi.org/10.1038/sj.bmt.1704024

TY - JOUR

T1 - Allogeneic bone marrow stem cell transplantation following CD34+ immunomagnetic enrichment in patients with inherited metabolic storage diseases

AU - Gaipa, G.

AU - Dassi, M.

AU - Perseghin, P.

AU - Venturi, N.

AU - Corti, P.

AU - Bonanomi, S.

AU - Balduzzi, A.

AU - Longoni, D.

AU - Uderzo, C.

AU - Biondi, A.

AU - Masera, G.

AU - Parini, R.

AU - Bertagnolio, B.

AU - Uziel, G.

AU - Peters, C.

AU - Rovelli, A.

PY - 2003/5

Y1 - 2003/5

N2 - T-cell depletion is an essential step in reducing the risk of graft-versus-host disease (GVHD) in patients with inherited metabolic storage diseases (IMSD) undergoing hematopoietic stem cell transplantation. This goal can be achieved either by selective removal of T cells or by positive selection of CD34+ cells. Large-scale preparations of purified CD34+ cells from bone marrow products have not been extensively described. We report our results with bone marrow CD34+ cell enrichment using the CliniMACS system in eight children with IMSD. The median recovery of positively selected CD34+ cells was 46.2% with a purity of 97.5%, and a residual T cell content of 0.04 × 106 . A median of 5.5 × 106/kg of CD34+ cells was infused. All patients engrafted at a median time of 12 days and none of the patients developed GVHD. This method is technically feasible and can be successfully used to transplant children with IMSD.

AB - T-cell depletion is an essential step in reducing the risk of graft-versus-host disease (GVHD) in patients with inherited metabolic storage diseases (IMSD) undergoing hematopoietic stem cell transplantation. This goal can be achieved either by selective removal of T cells or by positive selection of CD34+ cells. Large-scale preparations of purified CD34+ cells from bone marrow products have not been extensively described. We report our results with bone marrow CD34+ cell enrichment using the CliniMACS system in eight children with IMSD. The median recovery of positively selected CD34+ cells was 46.2% with a purity of 97.5%, and a residual T cell content of 0.04 × 106 . A median of 5.5 × 106/kg of CD34+ cells was infused. All patients engrafted at a median time of 12 days and none of the patients developed GVHD. This method is technically feasible and can be successfully used to transplant children with IMSD.

KW - Hematopoietic stem cell

KW - Immunomagnetic enrichment

KW - Storage diseases

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=0038621747&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704024

DO - 10.1038/sj.bmt.1704024

M3 - Article

C2 - 12748661

AN - SCOPUS:0038621747

SN - 0268-3369

VL - 31

SP - 857

EP - 860

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 10

ER -

Allogeneic bone marrow stem cell transplantation following CD34+ immunomagnetic enrichment in patients with inherited metabolic storage diseases

Abstract

Keywords

Access to Document

Fingerprint

Cite this